This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dridi, L.
Right arrow Articles by Petit, J.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dridi, L.
Right arrow Articles by Petit, J.-C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2002, p. 3418-3421, Vol. 46, No. 11
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.11.3418-3421.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

gyrA and gyrB Mutations Are Implicated in Cross-Resistance to Ciprofloxacin and Moxifloxacin in Clostridium difficile

Larbi Dridi, Jacques Tankovic,* Béatrice Burghoffer, Frédéric Barbut, and Jean-Claude Petit

Laboratoire de Bactériologie, Centre Hospitalo-Universitaire Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Université Paris VI, Paris, France

Received 12 April 2002/ Returned for modification 18 July 2002/ Accepted 13 August 2002

A total of 198 nonrepetitive clinical strains of Clostridium difficile isolated from different French hospitals in 1991 (n = 100) and 1997 (n = 98) were screened for decreased susceptibility to fluoroquinolones by plating onto Wilkins-Chalgren agar containing 16 µg of ciprofloxacin per ml. The frequency of decreased susceptibility was 7% (14 of 198) and was identical for the years 1991 and 1997. Serogroups C, H, D, A9, and K accounted for five, four, two, one, and one of the resistant strains, respectively, one strain being nontypeable. Arbitrarily primed PCR typing showed that all resistant strains had unique patterns except two serotype C strains, which could not be clearly distinguished. All isolates with decreased susceptibility carried a mutation either in gyrA (eight mutations, amino acid changes Asp71->Val in one, Thr82->Ile in six, and Ala118->Thr in one) or in gyrB (six mutations, amino acid changes Asp426->Asn in five and Arg447->Leu in one). These changes are similar to those already described in other species except for Asp71->Val, which is novel, and Ala118->Thr, which is exceptional. Attempts to detect the topoisomerase IV parC gene by PCR amplification with universal parC primers or DNA-DNA hybridization under low-stringency conditions were unsuccessful. The susceptibilities of all resistant strains to ciprofloxacin and ethidium bromide were not affected by the addition of reserpine at 20 µg/ml. In conclusion, decreased susceptibility to fluoroquinolones in C. difficile is rare in France and is associated with the occurrence of a gyrA or gyrB mutation.

* Corresponding author. Mailing address: Laboratoire de Bactériologie, Hôpital Saint-Antoine, 184 rue du Faubourg Saint-Antoine, 75 571 Paris Cedex 12, France. Phone: 33 (1) 49 28 29 10. Fax: 33 (1) 49 28 24 72. E-mail: jacques.tankovic{at}sat.ap-hop-paris.fr.

Antimicrobial Agents and Chemotherapy, November 2002, p. 3418-3421, Vol. 46, No. 11
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.11.3418-3421.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Spigaglia, P., Barbanti, F., Louie, T., Barbut, F., Mastrantonio, P. (2009). Molecular Analysis of the gyrA and gyrB Quinolone Resistance-Determining Regions of Fluoroquinolone-Resistant Clostridium difficile Mutants Selected In Vitro. Antimicrob. Agents Chemother. 53: 2463-2468 [Abstract] [Full Text]  
  • Saxton, K., Baines, S. D., Freeman, J., O'Connor, R., Wilcox, M. H. (2009). Effects of Exposure of Clostridium difficile PCR Ribotypes 027 and 001 to Fluoroquinolones in a Human Gut Model. Antimicrob. Agents Chemother. 53: 412-420 [Abstract] [Full Text]  
  • Spigaglia, P., Barbanti, F., Mastrantonio, P., Brazier, J. S., Barbut, F., Delmee, M., Kuijper, E., R. Poxton, I., on behalf of the European Study Group on Clostridi, (2008). Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C. difficile infections in Europe. J Med Microbiol 57: 784-789 [Abstract] [Full Text]  
  • Drudy, D., Quinn, T., O'Mahony, R., Kyne, L., O'Gaora, P., Fanning, S. (2006). High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile. J Antimicrob Chemother 58: 1264-1267 [Abstract] [Full Text]  
  • Rafii, F., Park, M., Novak, J. S. (2005). Alterations in DNA Gyrase and Topoisomerase IV in Resistant Mutants of Clostridium perfringens Found after In Vitro Treatment with Fluoroquinolones. Antimicrob. Agents Chemother. 49: 488-492 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»